Clinical Trials Directory

Trials / Unknown

UnknownNCT04403750

Combined Laser-surgical Technology of RRD Treatment

Combined Laser-surgical Technology of Rhegmatogenous Retinal Detachment Treatment

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
The S.N. Fyodorov Eye Microsurgery State Institution · Other Government
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Purpose: to assess the efficacy and safety of combined laser-surgical technology of RRD treatment

Detailed description

The study takes place in the S.N. Fyodorov "Eye Microsurgery" Federal State Institution located in Moscow, Russian Federation. The study will include 50 patients with rhegmatogenous retinal detachment due to a horseshoe-tear. In addition to the standard ophthalmological examination, all patients will undergo wide-field optical coherence tomography to determine the extension and localization of the vitreoretinal traction zone. The obtained data will be used to planning the 1st step of laser-surgical treatment. All patients will undergo a combined laser-surgical technology, which includes 3 steps: 1) Nd-YAG laser excision of the vitreoretinal traction zone 2) pneumatic retinopexy (10% C3F8) 3) barrier laser photocoagulation around retinal break after retinal attachment. The patients are going to be followed up for at least 1 year, the main outcome measures are postoperative primary and final anatomic outcome, BCVA and complications.

Conditions

Interventions

TypeNameDescription
PROCEDURECombined laser-surgical technology of RRD treatment1. Nd-YAG laser excision of the vitreoretinal traction zone 2. Pneumatic retinopexy (10% C3F8) 3. barrier laser photocoagulation around retinal break after retinal attachment (2-3 days after pneumatic retinopexy)

Timeline

Start date
2018-09-15
Primary completion
2020-06-25
Completion
2021-06-01
First posted
2020-05-27
Last updated
2020-05-29

Locations

1 site across 1 country: Russia

Source: ClinicalTrials.gov record NCT04403750. Inclusion in this directory is not an endorsement.